Harrow, Inc. (HROW) 株式分析

企業概要

Harrow, Inc. is an eyecare pharmaceutical entity dedicated to the discovery, development, and commercialization of ophthalmic pharmaceutical products within the United States market. The company operates specifically within the Healthcare sector, classified under the industry of Drug Manufacturers - Specialty & Generic, which focuses on niche therapeutic areas rather than broad-market pharmaceuticals. In terms of scale, Harrow, Inc. maintains a market capitalization of $1.39B, generates annual revenue of $272.30M, and employs a workforce of 373 individuals. These valuation and revenue figures indicate that the company has established a significant market presence as a specialty player, possessing substantial liquidity with $75.06M in cash reserves to support its R&D and commercialization efforts in the competitive ophthalmology landscape.

財務健全性

The company reported a revenue of $272.30M over the trailing twelve months, yet posted a net income of $-5,139,000, while maintaining an EBITDA of $48.82M. The substantial gap between the positive EBITDA and the negative net income reveals a significant cost structure impact from non-operating expenses or interest costs that erode bottom-line profitability despite strong operational cash generation. Harrow, Inc. demonstrates robust financial flexibility with free cash flow of $45.18M, indicating a strong ability to fund operations and investments without relying heavily on external capital markets. The company's margins display a diverse picture: a gross margin of 75.1% reflects efficient production and high-value product offerings, an operating margin of 17.5% suggests healthy control over operating expenditures, but a profit margin of -1.9% confirms that overhead or interest obligations are currently exceeding total net earnings. On the balance sheet, total cash of $75.06M is significantly lower than total debt of $251.98M, resulting in a debt-to-equity ratio of 483.72, which characterizes the balance sheet as highly leveraged relative to shareholders' equity. Liquidity is well-managed for short-term obligations given a current ratio of 2.20, meaning current assets are more than double current liabilities. Return on equity stands at -8.5% and return on assets is 4.8%, metrics that collectively reveal management is currently generating returns below the cost of equity and that asset utilization faces headwinds from the reported net loss position.

バリュエーション評価

Valuation metrics present a complex scenario where the trailing P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is 13.71. The disparity between the unavailable trailing P/E and the forward P/E of 13.71 implies that the market anticipates a significant turnaround in earnings trajectory to achieve positive profitability in the upcoming fiscal periods. The price-to-book ratio is 26.47, indicating that the market prices the company at a substantial premium over its book value, likely reflecting intangible assets, growth potential in the ophthalmic drug pipeline, or strategic positioning within the specialty sector. Alternative valuation metrics provide further context, with a price-to-sales ratio of 5.10 and an EV/EBITDA of 32.05, suggesting the market is willing to pay a high multiple for revenue and enterprise value relative to operating cash flows despite current unprofitability. Regarding trading range, the 52-week high is $54.85 and the 52-week low is $20.85, providing a full range of volatility over the past year for investors to gauge relative positioning. The beta value is 0.31, which indicates that the stock exhibits low price volatility relative to the broader market, moving with significantly less intensity than the overall market index during periods of fluctuation.

Growth & Income

The company experienced a revenue growth of 33.3% year-over-year, whereas earnings growth was -10.3%, indicating that revenue expansion is outpacing earnings recovery. This divergence implies that while top-line sales are accelerating rapidly, the bottom line has not yet caught up, likely due to the aforementioned negative net income and high leverage levels. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains earnings to fund its high cash burn or strategic investments in product development. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion in a specialized niche without current income distribution, relying on operational improvements to eventually bridge the gap between positive EBITDA and positive net income.